The use of lorcaserin in the management of obesity: a critical appraisal.
Obesity is a chronic disease with a high prevalence in both developed and developing countries. Effective management of this worldwide epidemic will have a significant impact on the health care system globally. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, remain a major component of weight-reduction programs. The development of pharmacotherapy for the management of obesity is still at the infancy stage. Side effects have been the key issue for anti-obesity drugs previously withdrawn from the market. The focus of this review, lorcaserin, is a selective serotonin receptor agonist that is currently undergoing Phase III evaluations. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in two recent clinical trials. The available evidence indicates that this drug does not show unwanted effects on heart valves or pulmonary artery pressure, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. Despite these promising results, additional experimental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity monodrug therapy by the US Food and Drug Administration.
Department of Pharmacology and Pharmacy, University of Hong Kong, People's Republic of China.
Bo
B
Bai
Yu
Y
Wang
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology*; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001552:Benzazepines; D017366:Serotonin Receptor Agonists; C506658:lorcaserin
N Engl J Med. 2010 Jul 15;363(3):288-90
20647205
Nat Rev Drug Discov. 2009 Nov;8(11):833-4
19876031
Circulation. 2008 Jul 22;118(4):428-64
18591433
PLoS Med. 2009 Apr 28;6(4):e1000058
19399161
Circulation. 2000 Dec 5;102(23):2836-41
11104741
Circulation. 2004 Nov 2;110(18):e463-70
15520330
Obes Rev. 2010 Aug;11(8):593-602
19922432
Endocrine. 2006 Feb;29(1):49-60
16622292
Public Health Nutr. 2007 Oct;10(10A):1200-5
17903331
JAMA. 2006 Feb 15;295(7):761-75
16478899
Nat Rev Endocrinol. 2010 May;6(5):255-69
20234354
Pharmacol Rev. 1994 Jun;46(2):157-203
7938165
Curr Top Med Chem. 2003;3(8):885-97
12678838
J Gastroenterol. 2009;44(12):1203-8
19728009
Eur J Pharmacol. 2006 Nov 21;550(1-3):149-54
17026993
Am J Hypertens. 1992 Jan;5(1):37-44
1736933
Br J Clin Pharmacol. 2010 Oct;70(4):523-36
20840444
J Pharmacol Exp Ther. 2008 May;325(2):577-87
18252809
Prev Med. 2005 Jun;40(6):769-78
15850878
Lancet. 2006 Nov 11;368(9548):1673-9
17098085
Lancet. 2007 Nov 17;370(9600):1706-13
18022033
Pharmacol Ther. 2006 Sep;111(3):674-706
16960982
Arq Bras Endocrinol Metabol. 2009 Mar;53(2):262-70
19466219
Obes Rev. 2010 May;11(5):371-9
19538441
N Engl J Med. 1997 Aug 28;337(9):635
9280830
J Med Chem. 2008 Jan 24;51(2):305-13
18095642
Lancet. 2005 Oct 1;366(9492):1197-209
16198769
Pharmacol Rev. 2007 Jun;59(2):151-84
17540905
JAMA. 2005 Oct 19;294(15):1960-3
16234503
Am J Pathol. 2002 Dec;161(6):2209-18
12466135
Psychopharmacology (Berl). 1988;96(3):289-95
3146763
Am J Clin Nutr. 2010 Nov;92(5):1257-64
20861173
Obesity (Silver Spring). 2009 Mar;17(3):494-503
19057523
Drug Metab Dispos. 1997 May;25(5):651-5
9152607
JAMA. 2005 Oct 19;294(15):1903-8
16234496
Ann N Y Acad Sci. 1990;600:558-72; discussion 572-3
2252335
Metabolism. 2009 Aug;58(8):1109-15
19454355
Pharmacol Ther. 1998 Sep;79(3):231-57
9776378
Eur Respir J. 2008 Feb;31(2):343-8
17959632
Diabetes Care. 2010 Oct;33(10):2156-63
20664019
Clin Neuropharmacol. 1988;11 Suppl 1:S51-71
3180109
Pain. 1990 Jan;40(1):115-116
2339009
Obes Res. 1998 Sep;6 Suppl 2:51S-209S
9813653
JAMA. 1999 Jan 20;281(3):235-42
9918478
J Med Chem. 1997 Aug 15;40(17):2762-9
9276022
N Engl J Med. 2010 Jul 15;363(3):245-56
20647200